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1. Introduction
Misalignment of circadian rhythms has been evidenced in patients with type 1 diabetes and
there is a close relationship between alterations in neuroendocrine sleep architecture, circa‐
dian clock oscillations, glucose metabolism, autonomic function, and diurnal profiles of
blood pressure and heart rate [1-5]. In turn, circadian misalignment may modify the peak
incidence of cardiovascular events in diabetic people [6-9]. Diabetic autonomic neuropathy,
particularly cardiac autonomic neuropathy, is considered an important potential factor in‐
volved in the disruption of circadian cardiovascular rhythms [10]. This serious chronic com‐
plication is rarely diagnosed because it remains for a long times asymptomatic; contrariwise,
it seems to have a significant prognostic value [10-12]. The review summarises the battery of
non-invasive autonomic function tests available for diabetic autonomic neuropathy diagno‐
sis as well as cross-sectional and follow-up studies supporting their importance in risk strat‐
ification for diabetic micro-vascular complications and cardiovascular morbidity/mortality.
2. A bit of history and a bit of anatomy
In 1973, the British Medical Journal and the Lancet published three articles on diabetic auto‐
nomic neuropathy [13-15], which would then be followed over the years by an unbroken
series of studies and publications. Wheeler and Watkins identified vagal denervation of the
heart as a feature of diabetic autonomic neuropathy that could be evaluated by monitoring
beat-to-beat variation in heart rate [14]. Ewing et al. found the vascular responses to the Val‐
salva manoeuvre and sustained handgrip useful in providing an objective assessment of the
integrity of the autonomic nervous system in diabetes [15]. Ewing himself later developed
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the cardiovascular autonomic function test battery still in use to provide an objective diag‐
nosis of autonomic nervous system involvement [16]. The battery included: Valsalva ma‐
noeuvre, heart rate response to standing up, heart rate response to deep breathing, blood
pressure response to standing up, and blood pressure response to sustained handgrip (Ap‐
pendix 1).
Brief description of the five non invasive cardiovascular reflex tests used by Ewing et al. [15] to assess autonomic func‐
tion in diabetic subjects.
Valsalva manoeuvre: the subject sits quietly and then blows in a mouthpiece at a pressure of 40 mmHg for 15 s. The
heart rate normally increases during the manoeuvre and decreases after release. The ratio of the longest R-R interval
shortly after the manoeuvre to the shortest R-R interval during the manoeuvre is measured.
Heart rate response to standing up: the subject lies quietly and then stands up unaided. The heart rate normally in‐
creases with a maximum at about the 15th beat after starting to stand and thereafter decreases with a minimum
around the 30th beat. Electrocardiogram tracings are used to determine the 30:15 ratio, calculated as the ratio of the
longest R-R interval around the 30th beat to the shortest R-R interval around the 15th beat.
Heart rate response to deep breathing: the subject sits quietly and then breathes deeply at a rate of six breaths per mi‐
nute. The maximum and the minimum heart rate during each breathing cycle are measured, and the mean of the dif‐
ferences during successive breathing cycles is measured.
Blood pressure response to standing up: the blood pressure is measured using a sphygmomanometer while the subject
is lying down and after standing. The difference in systolic blood pressure is a measure of postural blood pressure
change.
Blood pressure response to sustained handgrip: handgrip is maintained at 30% of the maximum voluntary contraction
up to a maximum of five minutes and the blood pressure is measured each minute. The difference between the diastol‐
ic blood pressure just before release of handgrip, and before starting, is measured.
Based on his 10-yr experience, Ewing et al. 1) stressed the fallacy of relying on a single test,
particularly heart rate variation during deep breathing, to make diagnosis of autonomic
neuropathy, and 2) stated that the previous classification of tests into parasympathetic and
sympathetic (Table 1), although clinically useful, should not be considered physiologically
precise because of the complexity of the autonomic pathways [16].
Blood flow adjustments are achieved by local vascular control mechanisms (mechanical
forces and chemical stimuli) but require to be coordinated by a remote central neural control
[17]. Autonomic motor control is effected by long parasympathetic preganglionic fibres and
short sympathetic preganglionic fibres that originate within the central nervous system. The
former synapse on short postganglionic fibres arising from ganglia located close to the effec‐
tor targets, the latter synapse on long postganglionic fibres arising from the paravertebral
chain ganglia or collateral ganglia. Parasympathetic neurons limit their influence mainly to
the control of cardiac function, whereas sympathetic neurons innervate the heart, blood ves‐
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sels, adrenal glands, and kidneys [17]. The arterial baroreflex modulates beat-to-beat blood
pressure oscillations: afferent baroreceptor discharge from the carotid sinus and aortic arch
is relayed to the nucleus tractus solitarius in the dorsomedial region of the medulla. As a
result, changes in the efferent sympathetic and parasympathetic outflow to the heart and
blood vessels adjust cardiac output and vascular resistance to return blood pressure to base‐
line. Similarly, the cardiopulmonary baroreceptors minimise changes in arterial blood pres‐
sure in response to changes in blood volume.
Cardiovascular tests in diagnosing diabetic autonomic neuropathy
Parasympathetic Sympathetic
Resting heart rate Resting heart rate
Heart rate response to deep breathing Blood pressure response to standing up
Heart rate response to standing up Blood pressure response to sustained handgrip
Valsalva manoeuvre Blood pressure response to cold
Spectral analysis of heart rate variation (high frequency
component)
Spectral analysis of heart rate variation (very low frequency
component)
Table 1. Classification of cardiovascular tests for the diagnosis of diabetic neuropathy.
The complexity of the autonomic pathways is exemplified by the following quotations. The
act of breathing modulates autonomic neural outflow from the brainstem, but the mecha‐
nisms underlying the respiratory sinus arrhythmia are still unclear [18]: only fluctuations in
efferent cardiac vagal activity or combined vagal/sympathetic heart rate modulation? More‐
over, is respiratory sinus arrhythmia driven by respiratory synchronous oscillations in blood
pressure via the arterial baroreflex or both respiratory sinus arrhythmia and blood pressure
are independently related to respiration via nonbaroreflex mechanisms?
Small negative changes of central volume reduce cardiac output without significant altera‐
tions of arterial blood pressure: 1) short-term cardiovascular control through respiratory si‐
nus arrhythmia and baroreflex feedback are optimised at mild hypervolemia; 2) both the
time and frequency domain data support the presence of a Bainbridge reflex (i.e. hypervole‐
mia-induced tachycardia) at moderately elevated levels of central volume, to reduce cardiac
preload under volume loading conditions. Finally, mild to moderate levels of hypovolemia
do not cause significant reductions in arterial pressure, explained in part by a mild tachycar‐
dia and increased feed forward gain from heart rate to arterial pressure [19].
Physical activity produces intensity-dependent increases in arterial blood pressure that are
mediated by central signals arising from higher brain centres and by peripheral feedback
from skeletal muscle (exercise pressor reflex) with further modulation provided by the arte‐
rial baroreflex. The sensory component of the exercise pressor reflex is comprised of myeli‐
nated group III and unmyelinated group IV skeletal muscle afferents that respond to both
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mechanical (mechanoreflex) and metabolic (metaboreflex) stimuli. However, the receptors
activating muscle afferent fibres as well as the factors contributing to a decrease in reflex ac‐
tivity in oxidative muscle are still not precisely characterised [20].
3. Current standards of medical care in diabetes
Up to 70% of people with diabetes experience nervous system damage in their lifetime. Dia‐
betic neuropathy compromises quality of life being a major contributing cause of lower limb
amputation (http://www.diabetes.org/diabetes-basics/diabetes-statistics/) [11, 21-22].
Diabetic neuropathy is considered to be a multifactorial process whose contributing factors,
yet not completely understood, are metabolic, vascular, autoimmune, oxidative and nitrosa‐
tive stress, and neuro-hormonal growth factor deficiency [20-21].
The classification of diabetic neuropathy that was originally proposed by Thomas [23] has
been recently adapted by Vinik [22, 24] (Table 2).
Clinical Presentation and Diagnosis Differential Diagnosis
Focal neuropathies Mononeuritis
Entrapment syndromes
Diffuse neuropathies Proximal motor (amyothrophy) Co-existing chronic inflammatory demyelinating
polyneuropathy
Monoclonal gammopathy of undetermined significance
Circulating GM1 antibodies and antibodies to neuronal
cells
Inflammatory vasculitis
Generalised symmetric
polyneuropathies
Acute sensory
Chronic sensorimotor
- Large fibre
- Small fibre
Autonomic
Table 2. Classification of diabetic neuropathy proposed by Vinik et al. [22].
Diabetic autonomic neuropathy is the least recognised and understood diabetic complica‐
tion: clinical symptoms generally do not appear until long after the onset of diabetes, but
subclinical autonomic dysfunction can occur within one year of diagnosis in type 2 diabetes
and within two years of diagnosis in type 1 diabetes [24]. Diabetic autonomic neuropathy
can involve the entire autonomic nervous system leading to a wide range of symptoms
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[21-22, 24]. Cardiac autonomic neuropathy can manifest as tachycardia (heart rate > 100
bpm), decreased exercise tolerance, orthostatic hypotension (a fall in systolic blood pressure
> 20 mmHg upon standing without appropriate heart rate response), cardiac denervation
syndrome with silent myocardial infarction, paradoxical supine or nocturnal hypertension,
intra- and peri-operative cardiovascular instability, left ventricular diastolic dysfunction.
Peripheral diabetic autonomic neuropathy can manifest as decreased thermoregulation, de‐
creased sweating, altered blood flow, impaired vasomotion, and oedema. From the metabol‐
ic point of view, there may be hypoglycaemia unawareness with decreased counter-
regulatory catecholamine responses as well as hypoglycaemia unresponsiveness with
reduction in glucagon and epinephrine secretion in response to hypoglycaemia. Gastrointes‐
tinal diabetic autonomic neuropathy can manifest as oesophageal dysmotility, gastro-paresis
diabeticorum, diarrhoea or constipation, faecal incontinence. Genitourinary symptoms in‐
clude erectile dysfunction, retrograde ejaculation, neurogenic bladder and cystopathy, fe‐
male sexual dysfunction. Sudomotor diabetic autonomic neuropathy may manifest as
anhidrosis, hyperhidrosis, heat intolerance, gustatory sweating, and dry skin. Pupillomotor
function impairment and pseudo-Argyll-Robertson pupil have also been described.
The American Diabetes Association [11] recommends that:
1. a comprehensive diabetes evaluation should include a history of diabetes related micro‐
vascular complications: retinopathy, nephropathy, and neuropathy (sensory, including
history of foot lesions; autonomic, including sexual dysfunction and gastro-paresis);
2. a comprehensive diabetes evaluation should include presence/absence of patellar and
Achilles reflexes as well as determination of proprioception, vibration, and monofila‐
ment sensation;
3. all patients should be screened for distal symmetric polyneuropathy at diagnosis of
type 2 diabetes and 5 years after the diagnosis of type 1 diabetes and at least annually
thereafter, using simple clinical tests. Electrophysiological testing is rarely needed, ex‐
cept in situations where clinical features are atypical;
4. screening for signs or symptoms of cardiac autonomic neuropathy should be instituted
at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes. Special
testing is rarely needed;
5. medications for relief of specific symptoms related to distal symmetric polyneuropathy
or diabetic autonomic neuropathy are recommended as they improve the quality of life
of the patient;
6. foot examination should include testing for loss of protective sensation, i.e. 10-g mono‐
filament plus testing for any one of the following: vibration using 128-Hz tuning fork,
pinprick sensation, ankle reflex, vibration sensation threshold.
Diabetic Autonomic Neuropathy and Circadian Misalignment in Type 1 Diabetes
http://dx.doi.org/10.5772/52033
363
4. Diagnostic tests of cardiovascular autonomic neuropathy
The presence of cardiac autonomic neuropathy may be indicated by resting tachycardia
(heart rate > 100 bpm) that is due to an imbalance of the sympathetic/parasympathetic tone.
Because neuropathy is seen first in the longest fibres, early in the natural history of diabetes
there is impairment of parasympathetic function, followed later by sympathetic denervation
that progresses from the apex of the ventricles towards the base of the heart and increases
the propensity to dysrhythmias [10, 25]. Moreover, cardiac autonomic neuropathy reduces
exercise tolerance by impairing heart rate, blood pressure, and cardiac output responses to
exercise. Indeed, subjects with diabetes and suspected cardiac autonomic neuropathy
should perform a cardiac stress test before undertaking an exercise program. The assump‐
tion of upright posture results in gravity-mediated displacement of blood into the veins of
the pelvis and lower limbs, reducing venous return to the heart. In healthy people, this leads
to a reflex increase in sympathetic nervous system activity, increasing peripheral vascular
resistance and heart rate such that arterial pressure is maintained [26]. In diabetic people,
sympathetic vasomotor denervation may lead to orthostatic hypotension that is aggravated
when combined with orthostatic bradycardia [25]. Moreover, a large proportion of diabetic
patients receive multi-drug therapy that potentially contributes to the fall in blood pressure
on assuming the upright posture [24]. Table 3 provides a list of drugs, which may interfere
with autonomic function tests.
In diabetes, analysis of 24-h ambulatory blood pressure monitoring (ABPM) showed altered
characteristics of blood pressure rhythm [1]. In particular, diabetic patients had a high prev‐
alence of increased night time blood pressure or non-dipping profile [27-32] that could re‐
flect a) the presence of autonomic neuropathy [32-33] resulting in sympathetic
predominance during sleep, but also b) the circadian misalignment due to obstructive sleep
apnoea in obese subjects with type 2 diabetes [34]. Chronobiologically interpreted ambulato‐
ry blood pressure monitoring uncovered that midline estimate statistic of rhythm (MESOR)
and mean of systolic blood pressure and diastolic blood pressure were higher in diabetic pa‐
tients than in healthy subjects [35-42]. Figures 1-2 show the relationship between heart rate
response to deep breathing and the circadian blood pressure rhythm parameters midline es‐
timate statistic of rhythm and acrophase.
Abnormalities in respiration-related heart rate variability can be evaluated in a number of
different ways, from the simple bedside tests of short-term heart rate differences previously
listed to the spectral analysis of heart rate variability, taking into account that normative val‐
ues of heart rate variability indices are affected mainly by age [10]:
1. Heart rate response to deep breathing, which measures sinus arrhythmia during quiet
respiration and primarily reflects parasympathetic function.
2. Heart rate response to standing up induces reflex tachycardia followed by bradycardia
and is both vagal and baroreflex mediated.
3. Valsalva manoeuvre evaluates cardio-vagal function in response to a standardized in‐
crease in intrathoracic pressure, primarily parasympathetic mediated.
4. Time domain measures of heart rate variability are summarised in Table 4[43]. In a con‐
tinuous ECG record, each QRS complex is detected, and the normal-to-normal (NN) in‐
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tervals (that is, all intervals between adjacent QRS complexes resulting from sinus node
depolarisations) or the instantaneous heart rate is determined.
5. Frequency domain measures of heart rate variability evaluate how power (variance)
distributes as a function of frequency using power spectral density (PSD) analysis (Ta‐
ble 5) [43]. Vagal activity is thought to contribute mainly to the high frequency (HF,
0.15-0.4 Hz) component, which is related to respiratory activity, while the sympathetic
system is thought to modulate the lower-frequency heart rate variability components.
The very low frequency (VLF, <0.04 Hz) components are related to fluctuations in vaso‐
motor tone associated with thermoregulation, and the low frequency (LF, 0.04-0.15 Hz)
components are considered to be associated with the baroreceptor reflex [10, 44].
6. QT interval prolongation in the ECG has been used to diagnose cardiac autonomic neu‐
ropathy with reasonable sensitivity, specificity and positive predictive value [12, 45] al‐
though there is no universal agreement on 1) QT measurement and correction
techniques, and 2) normality range [46]. Age dependency of cardiovascular autonomic
responses is exemplified in Figure 3. Figures 4-6 show the heart rate variability with
deep breathing, lying to standing, and Valsalva manoeuvre, respectively, in patients
with type 1 diabetes and control subjects.
Figure 1. The linear relationship between age and heart rate response to deep breathing expressed as expiratory/
inspiratory (E:I) ratio and systolic blood pressure (SBP)midline estimate statistic of rhythm (MESOR) in 20 patients with
type 1 diabetes and 25 age-matched control subjects.
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Figure 2. The linear relationship between age and heart rate response to deep breathing expressed as expiratory/
inspiratory (E:I) ratio and diastolic blood pressure (DBP) acrophase in the same subjects as in Figure 1.
Drug class Medication Effect on heart
rate
Effect on blood
pressure
Anti-inflammatory drugs acetylsalicylic acid x
Angiotensin converting enzyme inhibitors captopril x
enalaprin x
lisinopril x
quinalapril x
trandolapril x
Angiotensin II type 1 receptor blockers eprosartan x
losartan x
α-adrenoceptor antagonists doxazosin x
β-blockers atenolol x
bisoprolol x
metoprolol x
nebivolol x
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Drug class Medication Effect on heart
rate
Effect on blood
pressure
Calcium channel blockers diltiazem x
nifedipine x
verapamil x
Cardiac glycosides digoxin x
Diuretics furosemine, thiazides x
spironolactone x
Psychoactive drugs x
Benzodiazepines alprazolam x x
diazepam x
lorazepam
midazolam x
Tricyclic antidepressants amitriptyline x x
carbamazepine x
desipramine x x
doxepin x x
fluvoxamine x x
imipramine x x
nortriptyline x x
Table 3. Drug classes which may interfere with autonomic function tests and some examples of medications [12].
Variable Units Description
STATISTICAL MEASURES
SDNN ms Standard deviation (SD) of all normal-to-normal (NN) intervals
SDANN ms Standard deviation (SD) of the averages of normal-to-normal (NN) intervals in all 5-minute
segments of the entire recording
RMSSD ms Root-mean square of the differences of successive normal-to-normal (NN) intervals
SDNN index ms Mean of the standard deviations (SDs) of all normal-to-normal (NN) intervals for all 5-
minute segments of the entire recording
SDSD ms SD of differences between adjacent normal-to-normal (NN) intervals
NN50 count ms Number of pairs of adjacent normal-to-normal (NN) intervals differing by more than 50 ms
in the entire recording (counting all such NN intervals pairs or only pairs in which the first or
the second interval is longer)
pNN50 % NN50 count divided by the total number of all normal-to-normal (NN) intervals
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Variable Units Description
GEOMETRIC MEASURES
Heart rate
variability
triangular index
Total number of all normal-to-normal intervals divided by the height of the histogram of all
normal-to-normal (NN) intervals measured on a discrete scale with bins of 7.8125 ms (1/128
seconds)
Triangular
interpolation
(TINN)
ms Baseline width of the minimum square difference triangular interpolation of the highest
peak of the histogram of all normal-to-normal (NN) intervals
Differential
index
ms Difference between the widths of the histogram of differences between adjacent normal-
to-normal intervals measured at selected heights
Logarithmic
index
ms Coefficient ϕ of the negative exponential curve k · e-ϕt, which is the best approximation of
the histogram of absolute differences between adjacent NN intervals
Table 4. Time domain measures of heart rate variability described by the Task Force of the European Society of
Cardiology and the North American Society of Pacing and Electrophysiology. The four measures marked in grey were
recommended for time domain heart rate variability assessment [43].
Variable Units Description
ANALYSIS OF SHORT-TERM RECORDINGS
5-min total
power
ms2 The variance of normal-to-normal (NN) intervals over the temporal segment
VLF ms2 Power in very low frequency (VLF) range
LF ms2 Power in low frequency (LF) range
LF norm nu LF power in normalized units LF/(total power-VLF)x100
HF ms2 Power in high frequency (HF) range
HF norm nu HF power in normalized units HF/(total power-VLF)x100
LF/HF ms2 Ratio LF [ms2]/HF[ms2]
ANALYSIS OF ENTIRE 24 HOURS
Total power ms2 Variance of all normal-to-normal (NN) intervals
ULF ms2 Power in the ultra low frequency (ULF) range
VLF ms2 Power in the VLF range
LF ms2 Power in the LF range
HF ms2 Power in the HF range
α Slope of the linear interpolation of the spectrum in a log-log scale
Table 5. Frequency domain measures of heart rate variability described by the Task Force of the European Society of
Cardiology and the North American Society of Pacing and Electrophysiology [43].
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Figure 3. The linear relationship between age and heart rate response to deep breathing expressed as expiratory/
inspiratory (E:I) ratio.
Figure 4. Two-way box percentile plots of heart rate response to deep breathing expressed as expiratory/inspiratory
(E:I) ratio in 20 patients with type 1 diabetes (black box) and 25 age-matched control subjects (white box).
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Figure 5. Two-way box percentile plots of heart rate response to standing upcalculated as the ratio of the longest R-R
interval around the 30th beat to the shortest R-R interval around the 15th beat in 20 patients with type 1 diabetes
(black box) and 25 age-matched control subjects (white box).
Figure 6. A two-way box percentile comparison plot of heart rate response to Valsalva manoeuvre expressed as the
ratio of the longest R-R interval shortly after the manoeuvre to the shortest R-R interval during the manoeuvre in 20
patients with type 1 diabetes (black box) and 25 age-matched control subjects (white box)
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5. What kind of relationship is between cardiac autonomic neuropathy,
cardiovascular mortality, and albuminuria
Chronic misalignment between the endogenous circadian timing system and the behaviou‐
ral cycles may increase the risk of diabetes, obesity, cardiovascular disease and cancer [5] as
well as the presence of diseases may affect circadian rhythms. While cardiovascular events
generally occur in the early morning hours [47-48], abnormalities in the circadian pattern of
cardiovascular events in the diabetic population has been attributed to differences in the du‐
ration of diabetes and supposedly the variable extent of underlying diabetic autonomic neu‐
ropathy [6-9, 49]. In 1989 Hjalmarson et al. observed two peaks of symptom onset of acute
myocardial infarction for patients with diabetes: a peak, 28%, was discernible between 6:01
AM and 12:00 noon and a secondary peak, 25%, between 6:01 PM and midnight. In patients
over 70 years of age, smokers, diabetics, those receiving β-blockers, and women, the morn‐
ing and the evening peaks were of the same size [6]. Moreover, angina has long been consid‐
ered an unreliable index of myocardial infarction in diabetic patients with coronary artery
disease [50-51]. The prolonged anginal perception threshold in diabetic patients was sug‐
gested to be partly the result of damage to the sensory innervation of the heart [52]. In the
same 1990, to investigate the incidence and mechanism of painless myocardial ischemia on
exercise testing in diabetic patients, Murray et al. performed two studies: 1) retrospectively,
all exercise tests carried out in the hospital during the past 5 years were reviewed for silent
ischemia; 2) prospectively, diabetic patients with known or suspected coronary artery dis‐
ease underwent autonomic function testing and a second exercise test. They concluded that
silent myocardial ischemia on exercise testing was common among patients with diabetes
mellitus and was associated with severe autonomic dysfunction [53].
Ambulatory electrocardiographic monitoring in 60 patients with diabetes and coronary ar‐
tery disease, 25 of whom underwent also autonomic nervous system testing, evidenced that
1) silent ischemia was highly prevalent since 91% of all ischemic episodes were silent, and 2)
time of onset of ischemia followed a circadian distribution with a peak incidence in the
morning hours, except in patients with moderate to severe autonomic nervous system dys‐
function who did not demonstrate such a peak [7]. Using harmonic regression model to
evaluate the circadian variation of myocardial infarction symptom onset in patients (n =
3882) who were enrolled in the Onset Study, it was then confirmed that patients with type 1
diabetes and those with type 2 diabetes for 5 or more years had an attenuation of the morn‐
ing peak in acute myocardial infarction [9]. Authors concluded that inconsistency in obser‐
vation of such an effect in patients with diabetes in the past might well have been due to
differences in the duration of diabetes and thus the variable extent of underlying autonomic
dysfunction [9]. To exemplify inconsistencies among clinical observations, the time of onset
of ischemic pain in patients enrolled in the Thrombolysis in Myocardial Ischemia (TIMI) III
Registry Prospective Study and in the TIMI IIIB trial showed a circadian variation with a
peak in the morning hours between 6 AM and 12 noon. This circadian variation was ob‐
served both in patients with unstable angina and in those with evolving non-Q-wave acute
myocardial infarction and in all subgroups tested, diabetics included [8]. On the contrary, Li
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et al. showed there was no a significant morning peak of incidence of acute myocardial in‐
farction in patients with diabetes but was obvious in control subjects; however, disappear of
morning peak was not associated with duration of diabetes [49].
Mechanisms through which cardiovascular circadian rhythms may be altered in diabetes are
under current investigation. The tight crosstalk between components of circadian and meta‐
bolic cycles in mammals suggests that changes in nutrient-dependent signalling pathways
such as in metabolic disorders may transmit cues that affect cardiovascular rhythmicity
through transcriptional and non-transcriptional mechanisms [1, 54]. Moreover, a functional
antagonism between melatonin and insulin has been supposed on the basis of animal and
clinical studies. Melatonin inhibits insulin release through both the pertussis-toxin-sensitive
membrane receptors MT1 and MT2 and the second messengers 3',5'-cyclic adenosine mono‐
phosphate, 3',5'-cyclic guanosine monophosphate and inositol 1,4,5-trisphosphate. In turn,
increased insulin levels exert an inhibitory effect on the pineal gland and melatonin[55].
The relationship between cardiovascular prognosis and cardiac autonomic neuropathy has
been investigated for a long time since the rate of deaths within a mean follow-up of 5.8
years had been found five times higher in the diabetic patients with cardiac autonomic neu‐
ropathy than in the diabetic patients free from cardiac autonomic neuropathy; most of these
deaths were from cardiac causes [56]. The reasons why cardiac autonomic neuropathy af‐
fects quality and length of life are not well established, but cardiac autonomic neuropathy
has been found to be associated with exercise intolerance, silent myocardial ischemia, pro‐
longation of QT interval that may cause arrhythmias, decreased myocardial perfusion re‐
serve, left ventricular hypertrophy and diastolic dysfunction [24, 57-59]. The variability of
mortality rates revealed in the studies could be related to the study population, the modality
for assessing cardiac autonomic neuropathy, the criteria used to define the presence of car‐
diac autonomic neuropathy, and the length of follow-up [60]. In 2003, Maser et al. examined
by meta-analysis this relationship: 15 studies published from 1966 to 2001 could be included
whose follow-up ranged from 0.5 to 16 years. The study-specific relative risks for individu‐
als with cardiac autonomic neuropathy ranged from 0.91 to 9.20 with a pooled relative risk
for mortality of 3.45 for studies that used two or more measures to define cardiac autonomic
neuropathy, and of 1.20 for those studies defining cardiac autonomic neuropathy with one
measure of autonomic function [60].
Our Table 6 summarises the main studies of cardiac autonomic neuropathy and mortality/
morbidity in patients with diabetes mellitus restarting from the year 2001 onwards. In that
year, a 3-7 year (mean 4.5) follow up was obtained in 107 diabetic patients with no history of
myocardial infarction or angina, a normal ECG, and two or more additional risk factors,
who underwent ECG stress test, a thallium-201 myocardial scintigraphy with dipyridamole,
and 48-h ECG monitoring to assess silent myocardial ischemia. In addition, cardiac auto‐
nomic neuropathy was searched for by standardized tests evaluating heart rate variations
[61]. The study confirmed that 1) the prevalence of type 1 silent myocardial ischemia was
high (about 30%) and significant coronary stenoses were found in approximately one-third
of those patients with silent myocardial ischemia; 2) there was only a trend of higher risk of
major cardiac events in the diabetic patients with silent myocardial ischemia than in the dia‐
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betic patients without silent myocardial ischemia; 3) cardiac autonomic neuropathy was sig‐
nificantly associated with an increased risk of major cardiac events. According to the
Kaplan-Meier method, the increase in the risk of major cardiac events linked to cardiac auto‐
nomic neuropathy was significant after adjusting for silent myocardial ischemia, but the
highest rate was found in patients who had silent myocardial ischemia and cardiac auto‐
nomic neuropathy. Authors concluded that the poor cardiovascular prognosis related to car‐
diac autonomic neuropathy in previous studies was probably associated with undetected
silent myocardial ischemia in many patients [61].
Ref. Follow up
(years)
Sample size Tests of CAN Definition
of CAN
Results Comments
61 4.5 107 patients
(of whom 17
with T1DM)
and normal
ECG
HR variability during
deep breathing,
Valsalva and lying to
standing tests
The results
were
compared
with those
from an age-
matched
control series
CAN was a better predictor of
major cardiac events (odds
ratio 4.30, 1.07-17.31) than
silent myocardial ischemia
(evaluated by ECG stress test,
myocardial scintigraphy with
dipyridamole, and 48-h ECG
monitoring)
Limited number of
asymptomatic patients with
predominantly T2DM
62 3.5 532 patients
with DM (483
with T2DM)
HR variability during
deep breathing; SBP
decrease during
standing
Not stated Increased all-cause mortality
associated with the lowest
quintile of HR variability
(hazard ratio 1.49, 1.01-2.19)
The cohort was
predominantly male; no
direct adjustment for use of
cardio-active medications
63 2.5 715 survivors
of AMI (117
with DM)
Spectral analysis of HR
variability (24-h Holter
ECG)
According to
cutpoints
previously
established
Decreased HR variability
remains predictive also in
diabetic patients (hazard ratio
for SDNN < 50 ms 2.56,
1.26-5.19)
Moderate power due to the
small number of death in
diabetic patients; DM was
not classified
65 5.3 872 of 950
patients with
T2DM
underwent
baseline
neuropathy
assessment
HR variability during
deep breathing
According to
age-related
range values
Borderline or abnormal
expiratory/ inspiratory ratio at
baseline was associated with
the occurrence of stroke
(hazard ratio 2.3, 1.17-4.70)
Only one autonomic test
instead of a battery
66 3.8 146 patients
with T2DM
with
suspected
coronary
artery disease
Deep breathing,
Valsalva manoeuvre,
lying to standing,
postural systolic blood
pressure change,
handgrip test
Three or
more of the
tests were
abnormal
Although perfusion defects
remained a strong predictor of
cardiac risk, CAN predicted the
occurrence of death and
cardiac events independent of
perfusion defects
Retrospective design;
limited number of subjects;
symptomatic diabetic
patients
67 15 311 patients
with T2DM
and 151
patients with
T1DM
Quantitative
sudomotor axon reflex
test, HR response to
deep breathing and to
the Valsalva
manoeuvre, BP
responses during tilt
and the Valsalva
manoeuvre
According to
the 10 point
score
composite
autonomic
severity scale
(CASS)
Sudden cardiac death relates
more directly to coronary
ischemia, cardiac arrhythmia, or
nephropathy than it does to
diabetic autonomic neuropathy
Northern European sample;
unavailable serial data
obtained before and during
sudden cardiac death; not
all applicable risk factors
could be modelled
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Ref. Follow up
(years)
Sample size Tests of CAN Definition
of CAN
Results Comments
68 10.1 388 patients
with T1DM of
whom 197
with diabetic
nephropathy
HR variability during
deep breathing
HR variability
< 10 bpm
CAN predicted cardiovascular
mortality and morbidity in
patients with diabetic
nephropathy (hazard ratio 6.4,
1.5-26.3), but not all-cause
mortality
CAN determined by only
one test, but well
characterised population
69 9.2 104 patients
with T2DM of
whom 51
with diabetic
nephropathy
HR variability during
deep breathing
Not stated Non-dipping phenomenon
predicted all-cause mortality
(1% increase in dipping was
associated with a lower risk
0.97, 0.94-0.998); HR variability
was confirmed to be a
predictor also in T2DM (1 bpm
increase 0.92, 0.87-0.98)
Low patient number, but
well characterised
population
70 9.0 1560 non
diabetic and
160 diabetic
subjects
(MONIKA/
KORA Study)
Time domain
measures, corrected
QT interval, and QT
dispersion were
obtained from a 12-
lead resting ECG
Not stated The relative risk of mortality in
subjects with corrected QT >
440 ms increased by twofold
and threefold in the non
diabetic and diabetic group,
respectively; prolonged QT
interval predicted
cardiovascular mortality only in
the non diabetic group (risk
ratio 4.47, 2.44-9.22)
Short period of ECG
recording (20s) without
control for respiration
71 7.1 1458 patients
with T2DM
HR variability during
deep breathing,
Valsalva manoeuvre
and postural change
According to
age-related
reference
values (total
maximum
CAN score of
3)
Hazard ratio for acute stroke
events in patients with
abnormal CAN scores was 2.7
compared with patients with
normal scores; a CAN score of 3
was significantly associated
with a new ischaemic stroke
event in patients with diabetes
Lack reference values for
CAN tests specific for
Korean people; the effect
of glycaemic control status
on the development of
stroke has not been
assessed; limited number of
events
71 13.6 490
individuals
from a
population-
based cohort
(Hoorn Study)
of whom 135
with T2DM
HR variability during
deep breathing and
standing up, 5 tests of
spectral analyses of HR
variability, and one
baroreflex sensitivity
measurement
Cardiovascul
ar autonomic
dysfunction
total score
Both microalbuminuria and
CAN are independently
associated with cardiovascular
mortality, and the excess
mortality attributable to
microalbuminuria cannot be
explained by CAN
Moderate level of
reproducibility of
autonomic function
parameters; CAN total
score evaluated at baseline
only; spectral analyses
performed during 3 min;
albumin/creatinine ratio
measured in one urine
sample only
72 15.5 178 diabetic
patients of
whom 110
with T2DM
HR variability during
deep breathing,
Valsalva manoeuvre,
and lying to standing,
postural systolic blood
pressure change,
diastolic blood
pressure response to
handgrip test
Two or more
abnormal
tests
The relative risk of all-cause
mortality associated with CAN
was 2.85, 1.75-4.65; Valsalva
ratio and handgrip had an
independent predictive value
Sources of lower sample
representativeness: 1) 26%
of invited subjects refused
to participate (older than
responders), 2) patients’
ability to cooperate to the
function tests
73 15.5 165 diabetic
patients of
Time and frequency
domain parameters
Not stated The low frequency band in the
frequency domain was the
most powerful predictor of all-
Sources of lower sample
representativeness: 1) only
patients who completed all
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Ref. Follow up
(years)
Sample size Tests of CAN Definition
of CAN
Results Comments
whom 97
with T2DM
based on 24-hour ECG
recordings
cause mortality (estimated
relative risk of death with an
increase by 1 standard
deviation 0.65)
5 function tests and had an
acceptable 24-hour ECG
recording could be
analysed, 2) ECG was
recorded during normal
daily activity
74 15.5 136 diabetic
patients of
whom 77
with T2DM
Five autonomic
function tests together
with time and
frequency domain
parameters based on
24-hour ECG
recordings
Not stated Three simple autonomic
function tests (Valsalva, 30:15,
and handgrip) were superior to
HR variability in predicting all-
cause mortality in the diabetic
population
Sources of lower sample
representativeness: 1)
percentage of invited
subjects who refused to
participate (older than
responders), 2) patients’
ability to cooperate to the
function tests and to have
an acceptable 24-hour ECG
recording
Table 6. Studies that evaluated mortality and morbidity in patients with diabetes mellitus and cardiovascular
autonomic neuropathy (CAN) from 2001 onward. AMI, acute myocardial infarction; DM, diabetes mellitus; SBP,
systolic blood pressure; SDNN, standard deviation of normal RR intervals; T2DM, type 2 diabetes mellitus; T1DM, type
1 diabetes mellitus.
Wheeler et al. evaluated short-term all-cause mortality in an elderly cohort of predominant‐
ly male veteran patients with diabetes [62]. Among the 532 patients with RR variability
measures (evaluated by heart rate response to timed deep breathing), subjects who died (n =
120) had significantly lower heart rat variability than survivors. The lowest quintile of heart
rate variability with deep breathing was found to be associated with a 50% increase in mor‐
tality. After adjusting for age, smoking status, creatinine, pack-year of cigarettes smoked,
diabetes duration, race, history of ischemic heart disease, and hypertension, the hazard ratio
was 1.49 with a 95% confidence interval 1.01-2.19 [62].
Whang et al. used data from the Multicenter Post Infarction Program (MPIP, a longitudinal
observational study of 715 survivors of acute myocardial infarction, including 117 diabetic
patients, enrolled from 1979 to 1980) to test two hypotheses: 1) RR interval variability was
lower in diabetic patients, and 2) low RR interval variability was less predictive of mortality
in diabetic patients [63]. Six frequency-domain measurements and one time-domain meas‐
urement of RR interval variability were evaluated on the basis of 24-hour Holter electrocar‐
diographic recordings. Reduced RR interval variability was significantly more frequent in
diabetic patients than in non-diabetic patients for all measurements except high frequency
power. Moreover, in diabetic patients, the association between reduced RR interval variabil‐
ity and all-cause mortality was at least as strong as it was in non-diabetic patients for all
measurements except high frequency power [63].
Since the risk of fatal and non-fatal strokes were increased in diabetic patients compared with
non-diabetic patients over a 7-year follow up period [64], Cohen et al. evaluated the relation‐
ship between a number cardiovascular risk factors in normotensive and hypertensive type 2
diabetic patients (enrolled in the Appropriate Blood Pressure Control in Diabetes trial) on the
incidence of stroke [65]. Cardiovascular risk factors included also autonomic function testing,
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and automated electrocardiographic measure of heart rate response to deep breathing. Expir‐
atory/inspiratory (E:I) ratio was categorised as normal (53.6%), borderline (9.5%), or abnor‐
mal (36.9%) based on age-related range values. The presence of a borderline or abnormal
expiratory/inspiratory ratio at baseline was significantly associated with the occurrence of
stroke in the follow up period (hazard ratio 2.3, 1.17-4.70). Thus, diabetic autonomic neuropa‐
thy was a significant independent risk factor also for the occurrence of stroke [65].
In order to investigate the prognostic value of cardiac autonomic neuropathy in relation to
myocardial perfusion defects, Lee et al. evaluated 146 consecutive patients with type 2 dia‐
betes mellitus who underwent thallium-201 single photon emission computed tomography
(SPECT) for suspected coronary artery disease and who tested for autonomic nerve function
within three months of the single photon emission computed tomography study [66]. Car‐
diac autonomic function tests included deep breathing, Valsalva manoeuvre, lying to stand‐
ing, postural systolic blood pressure change, and handgrip test; cardiac autonomic
neuropathy was defined by the presence of ≥ 3 abnormal tests. Patients were followed up for
46±24 months to record deaths and major cardiac events. Significant predictors of death
were perfusion defects, cardiac autonomic neuropathy, and older age; significant predictors
of cardiac events were perfusion defects, cardiac autonomic neuropathy, hypertension, and
longer history of diabetes [66].
Suarez et al. investigated the risk factors for sudden cardiac death in the prospective, popu‐
lation based, Rochester Diabetic Neuropathy Study (RDNS) cohort: 462 diabetic patients (of
whom 115 with type 1 diabetes) were followed up over 15 years [67]. At baseline, patients
underwent 1) neuropathy assessment by the neuropathy impairment score, neuropathy
symptoms and change score, nerve conduction studies, and quantitative sensation; 2) auto‐
nomic neuropathy assessment by quantitative sudomotor axon reflex test, heart rate varia‐
bility to deep breathing and to the Valsalva manoeuvre, beat to beat blood pressure
responses during tilt and the Valsalva manoeuvre; 3) assessment of other putative risk fac‐
tors, metabolic control, diabetic retinopathy and nephropathy; 4) recording of a 12-lead ECG
every two years. The medical records, death certificates, and necropsy reports of all deaths
were reviewed and 21 cases of sudden cardiac death were identified. In bivariate analysis of
risk covariates, evolving and previous myocardial infarction, bundle branch block or pacing,
and nephropathy stage were stronger risk covariates than were indicators of diabetic auto‐
nomic neuropathy and HDL cholesterol. In bivariate analysis and adjusting for nephrop‐
athy, diabetic autonomic neuropathy was not statistically significant factor [67].
In a prospective observational follow up study, Astrup et al. evaluated the predictive value
of cardiac autonomic neuropathy for cardiovascular mortality and morbidity (primary end
point), all cause mortality and progression of diabetic nephropathy (secondary end points)
in 197 patients with type 1 diabetes and diabetic nephropathy and 191 patients with long
standing diabetes and normoalbuminuria who were followed for 10.1 years [68]. After ad‐
justment for cardiovascular risk factors, autonomic dysfunction was a predictor of cardio‐
vascular mortality and morbidity in type 1 diabetic patients with diabetic nephropathy
(hazard ratio 6.4, 1.5-26.3), whereas the impact of heart rate variability on all-cause mortality
was not significant. Moreover, there was no correlation between abnormal heart rate varia‐
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bility and rate of decline of glomerular filtration rate [68]. One year later, Astrup et al. pub‐
lished the results of a study aimed at evaluating the prognostic significance of
cardiovascular risk factors, including cardiac autonomic neuropathy and 24-hour blood
pressure level and rhythm, for all-cause mortality in type 2 diabetic patients (n = 104) with
and without diabetic nephropathy [69]. In a Cox regression analysis, predictors of all-cause
mortality included cardiac autonomic neuropathy (1 beat/min increase 0.92, 0.87-0.98) to‐
gether with age, male sex, left ventricular hypertrophy, haemoglobin A1c, daytime systolic
blood pressure, glomerular filtration rate (or albuminuria, alternatively) and dipping (1% in‐
crease in dipping was associated with a lower risk 0.97, 0.94-0.998). After adjusting for tradi‐
tional cardiovascular risk factors, non-dipping of night blood pressure remained a
significant predictor of all-cause mortality [69].
Prolonged QT corrected (QTc > 440 ms) interval was an independent predictor of mortality
over 9 years in the non-diabetic (n = 1560) and diabetic (n = 160) elderly general population
of the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) study,
whereas QT dispersion did not predict mortality in non-diabetic or diabetic subjects. On the
contrary, reduced heart rate variability appeared to be a more specific marker only in the
diabetic elderly general population [70]. Ko et al. investigated whether cardiac autonomic
neuropathy was associated with acute ischaemic stroke in 1458 patients with type 2 diabetes
during 7.1 year follow up [71]. At follow-up, 131 patients (11.6%) had developed newly di‐
agnosed acute ischaemic stroke. Baseline cardiac autonomic neuropathy score was signifi‐
cantly associated with the development of ischaemic stroke in patients with type 2 diabetes.
Indeed, the hazard ratio for acute stroke events in patients with abnormal cardiac autonomic
neuropathy scores was 2.7 compared with patients with normal scores [71]. In order to in‐
vestigate whether cardiac autonomic neuropathy could explain the relationship between mi‐
croalbuminuria and cardiovascular mortality, 490 individuals from a population-based
cohort (Hoorn Study) were followed for a median period of 13.6 years [72]. At baseline,
were evaluated glucose tolerance status, HbA1c, and albuminuria. Cardiovascular autonom‐
ic function tests included four tests that reflected heart rate or blood pressure changes due to
deep breathing or standing up, five tests of spectral analyses of heart rate variability, and
one baroreflex sensitivity measurement. Both microalbuminuria and cardiac autonomic neu‐
ropathy were independently associated with cardiovascular mortality. However, after ad‐
justment for age, sex, glucose tolerance status, and other cardiovascular risk factors,
microalbuminuria (relative risk 1.33, 0.83–2.13), in contrast to cardiovascular autonomic dys‐
function total score (1.52, 1.11–2.09), was not independently associated with all-cause mor‐
tality. The excess of mortality attributable to microalbuminuria could not be explained by
cardiac autonomic neuropathy [72].
Finally, May and Arildsen have evaluated long-term predictive power on all-cause mortality
of five function tests for cardiac autonomic neuropathy as well as of heart rate variability
based on 24-hour ECG recordings (both time domain analyses and frequency domain analy‐
ses were performed) in the same sample during a 15.5-year follow up period [73-75]. When
considering the five function tests for cardiac autonomic neuropathy (heart rate variability
during deep breathing, Valsalva manoeuvre, and lying to standing, postural systolic blood
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pressure change, diastolic blood pressure response to handgrip test) it was apparent that the
relative risk of all-cause mortality associated with cardiac autonomic neuropathy was 2.85,
1.75-4.65; Valsalva ratio, heart rate response to standing up (30;15 ratio), and handgrip had an
independent predictive value with regard to long-term all cause mortality [73]. When consid‐
ering separately time and frequency domain parameters of heart rate variability calculated on
the basis of a 24-hour ECG recording, the power in the low frequency band was the only heart
rate variability parameter with an independent predictive value on all-cause mortality [74].
When considering long-term predictive power of heart rate variability together with a battery
of five autonomic function tests, the latter ones were superior to the former ones; particularly,
Valsalva, 30:15 ratio, and handgrip were independent predictors of death [75].
6. Concluding remarks
Several studies have evaluated the predictive value of various cardiac autonomic neuropa‐
thy parameters for all cause mortality and/or cardiovascular mortality and morbidity. They
almost all agree that cardiac autonomic dysfunction is associated with a high-risk excess
mortality/morbidity in diabetic patients. Toward a general consensus, however, many chal‐
lenges remain to be addressed by the research community. Drawbacks and limitations main‐
ly concern the following features that deserve attention and discussion [76]:
1. Establishing appropriate study design for evaluating the particular association. Pro‐
spective cohort studies are considered less vulnerable to bias than retrospective studies,
because the outcomes have not occurred when the cohort is assembled and the expo‐
sures are assessed. In cohort studies the population may be fixed or open: undoubtedly,
in long-term follow ups, the prevalence of cardiac autonomic neuropathy progressively
increases in a direct proportion to age, duration of diabetes, and poor glycaemic control.
2. Defining clear health outcomes that should require confirmation by masked investiga‐
tors in order to guarantee their accuracy.
3. Establishing the length of follow up interval, which depends on the particular outcome
under study. It has been shown that the longer the follow up, the higher the likelihood
of attrition.
4. Calculating the required sample size on the basis of anticipated differences between the
groups, the background rate of the outcome, and the probability of making some statis‐
tical errors.
5. Using suitable cardiovascular autonomic reflex tests to diagnose cardiac autonomic
neuropathy taking into account that a) the diagnostic definition of cardiac autonomic
neuropathy based on several tests (of both vagal and sympathetic functions) reduces
the probability of false positives, b) the gold standard for clinical autonomic testing in‐
cludes heart rate response to deep breathing, standing, and Valsalva manoeuvre, and
blood pressure response to standing [12].
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6. Identifying in advance the various cardiovascular prognostic factors (how many and
which ones?) to reasonably adjust for in the analysis. Risk adjustment is essential to
making fair comparisons and first requires strict definition of each specific outcome,
particularly in diabetic people provided the complex association of traditional, non-tra‐
ditional and disease-specific risk factors with mortality/morbidity.
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